Compare Novo Nordisk A/S (NVO) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs TKO Group Holdings Inc — how do they compare? Novo Nordisk A/S trades at $46.25 (market cap $207.85B), while TKO Group Holdings Inc trades at $195.56 (market cap $14.24B). The key difference: Novo Nordisk A/S is far larger — about 14.6× TKO Group Holdings Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| NVO | TKO | |
|---|---|---|
Market Cap | $207.85B | $14.24B |
Sector | Health | Technology |
52-Week High | $63.98 | $224.96 |
52-Week Low | $35.29 | $176.49 |
Enterprise Value | $222.55B | $18.60B |
Dividend Yield | 3.81% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVO trades at $47.73, up 0.99% today, with a neutral technical signal and strong fundamentals, including a P/E of 11.62 and net income margin of 35.35%. Recent Q2 2026 earnings beat expectations, but the stock faces mixed sentiment due to competitive pressures and pricing headwinds in its GLP-1 portfolio.
The outlook is cautiously optimistic, supported by robust profitability and analyst buy ratings (57.9%), but risks include intense competition from Eli Lilly and margin compression. Upside potential hinges on execution against guidance, while downside risks stem from market share erosion.
TKO trades at $194.10, up 2.47% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 results showed revenue growth of 18% year-over-year to $1.55 billion, though EPS of $1.34 missed estimates. The company raised full-year guidance, reflecting confidence in media rights and live events. Valuation metrics like a P/E of 68.33 appear elevated relative to earnings.
The outlook is positive given raised guidance and dominant market position in sports entertainment, but high valuation and recent earnings misses pose risks. Upside to the consensus price target of $228.17 suggests potential growth, dependent on execution of growth initiatives and macroeconomic stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
